Indication:Common malignancies .
Clinical Commissioning Urgent Policy Statement: Pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies
NHS England Nov 2020.
Saftey update 2020 – Pharmacovigilance Risk Assessment Committee (PRAC) provides new testing and treatment recommendations for fluorouracil, capecitabine, tegafur and flucytosine. Patients receiving iv or intraarterial fluorouracil, or capecitabine or tegafur (both prodrugs of FU), should be tested for lack of dihydropyrimidine dehydrogenase (DPD) before starting treatment-lack of DPD may lead to fluorouracil toxicity eg neutropenia, neurotoxicity.